We are a bioanalytical lab that has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve.
Choose the program that fits your needs:
Complete COVID-19 Workforce Testing
An end-to-end service for return-to-work & on-going employee safety screening.
COVID-19 Testing for Clinical Development
Offering the complete suite of assays & services needed to detect and characterize responses to SARS-CoV-2.
Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.
Biomarkers
Immunogenicity
Pharmacokinetics & Pharmacodynamics (PK/PD)
Cell-Based Assays
Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.
Biosimilars
Gene Therapy
Antibody Drug Conjugates (ADCs)
Immuno-oncology
In this Q&A, BioAgilytix’s Mark Bethers, Dr. Chad Briscoe & Dr. Linda Robbie take a closer look at strategies for COVID-19 workforce testing. Watch the on-demand recording to learn how your organization can develop a complete, effective COVID-19 employee testing strategy that gives timely, reliable, data-driven insight to mitigate COVID-19 exposure risk.
Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.
Quick links to our latest content offerings:
November 13, 2020Difference Between Biobetters and Biosimilars
October 22, 2020The Impact of Brexit on European Biotech and Biopharma
October 30, 2020BioAgilytix Bioanalytical Lab Welcomes the Phadia 200 to Its Hamburg Laboratory
October 29, 2020Governor Cooper Announces 878 New Jobs as BioAgilytix Chooses Durham for Major Expansion
August 6, 2020Analytical Assays Determine Biosimilar Product Quality
December 2, 2019Immunogenicity Assessment of Gene Therapy Compounds
Services
Platforms